“The current condition has exposed some structural weaknesses in the EU’s medicines offer chain plus a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She advisable that offer chain difficulties be dealt with within an EU pharmaceutical approach predi